This study aims to establish and validate radiomics models based on clinical features and MRI scans of EGFR-mutated lung adenocarcinoma patients with brain metastases prior to receiving third-generation EGFR-TKI treatment, in order to predict short-term efficacy and iPFS, helping clinicians to identify high-risk patients in a timely manner and adjust diagnostic and treatment strategies accordingly. The gene discussed is EGFR; the disease is lung adenocarcinoma.